Related Experiment Video
Updated: Jun 28, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Digital Health Technology (DHT) in European Clinical Trials, How to Improve the Status-Quo of the Regulatory
1Bayer AG, Research & Development, Pharmaceuticals, Regulatory Affairs, MD, Berlin, Germany. hans-peter.podhaisky@bayer.com.
Abstract:
Digital health technology (DHT) is increasingly used to facilitate the conduct of clinical drug trials. The European regulatory environment would benefit from some adjustments to realize the full potential of DHTs. Considering current discussions such as the European Accelerating Clinical Trial Initiative (ACT EU), we propose four concrete adjustments to this regulatory landscape to introduce risk-based qualification approaches for DHTs. In our view, these changes would have the potential to facilitate the use of DHT in clinical research and thus provide access to innovative therapies in Europe.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

